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Purpose: Insulin-like growth factors (IGFs) regulate a wide range of biological functions including cell proliferation, differ-
entiation, and apoptosis through paracrine and autocrine mechanisms. Accordingly, the present study analyzed poly-
morphisms of IGF genes and their impact on the prognosis for patients with gastrointestinal stromal tumors (GISTs). 
Methods: Two hundred-thirteen consecutive patients with GISTs who underwent curative surgery from 5 medical centers 
were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tumor tissue, and four IGF-1 
(＋2995C/A, ＋533C/T, IVS2-16540A/G, Ex4-177G/C) and one IGF-2 (IVS1＋1280A/G) gene polymorphisms were determined 
using a Sequenom MassARRAY system. Results: With a median follow-up of 18.4 months, the estimated 5-year relapse-free 
survival and overall survival rates were 69.9% and 86.7%, respectively. In a multivariate analysis including age, gender, pri-
mary site of disease, pathology, and risk stratification, no significant association was observed between the polymorphism of 
the IGF-1 and IGF-2 genes and survival. Conclusion: None of the five IGF-1 and IGF-2 gene polymorphisms investigated in 
this study was found to be an independent prognostic marker for Korean patients with surgically resected GIST. However, 
further studies on a larger scale are warranted to clarify the role of IGF-1 and IGF-2 gene polymorphisms as a prognostic bio-
marker for GIST patients.
Key Words: Gastrointestinal stromal tumor, Insulin-like growth factor, Single nucleotide polymorphism, Prognosis
INTRODUCTION
The insulin-like growth factor (IGF) and its family play 
a key role in the growth and development of normal tissue 
and regulate a wide range of biological functions, such as 
cell proliferation, differentiation, and apoptosis, through 
paracrine and autocrine mechanisms [1]. In particular, IGF 
receptor-mediated initiation of signal transduction also 
activates important intracellular signal pathways in solid 
tumors, including the Ras/Raf/mitogen-activated protein IGF-1 and IGF-2 polymorphism in GIST
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kinase and phosphoinositide 3-kinase pathway [2]. Previ-
ous studies have shown that an increased expression of 
IGF or its family is associated with the grade of tumor 
growth and the prognosis for various solid tumors [3-6]. 
Recently, the targeting for IGF has emerged as an im-
portant solution for the resistance that arises after targeted 
treatment.
Gastrointestinal stromal tumors (GISTs) represent a 
heterogenous group of tumors that originate from the in-
terstitial cells of Cajal in the nerve plexus of the muscularis 
in the gastrointestinal wall [7]. GISTs are characterized by 
KIT and platelet-derived growth factor alpha (PDGFRA) 
receptor abnormalities that represent the key oncogenic 
event, as well as the most important therapeutic target [8]. 
Recently, IGF or its family has emerged as a novel molec-
ular signaling pathway other than KIT and PDGFRA on 
GISTs [9]. The expression of IGF-1 and IGF-2 family has al-
so been shown to be correlated with a poor prognosis for 
GISTs [10]. In addition, epidemiologic studies have in-
dicated that high plasma IGF-1 plays a role in energy bal-
ance, which has also been shown to influence risk for solid 
tumors including GIST [11]. Thus, given these results, IGF 
or its family would seem to play an important role in tu-
mor growth and spread, thereby affecting the prognosis 
for GISTs. 
Single nucleotide polymorphisms (SNPs) have already 
been widely implicated in cancer development, prognosis, 
and treatment response, yet similar evidence is lacking for 
IGF genes. Although IGF-1 tag SNPs have been associated 
with circulating  IGF-1 levels, the functional polymor-
phisms that might be mediating these associations have 
not been identified [12]. Wong et al. [13] reported that a pu-
tative regulatory IGF-1 in the promoter region is asso-
ciated with reduced colorectal cancer risk. In addition, 
IGF-1 haplotype and the IGF2 Ex4-233 C/T polymorphism 
was also found to be significantly associated with risk of 
pancreatic cancer [14]. 
To date, only a few studies have been published in re-
gards with the relationship between the SNP of IGF or its 
family gene and clinical outcomes of GISTs. Therefore, the 
present study analyzed five IGF-1 and IGF-2 gene poly-
morphisms and their effect on the prognosis for GIST 
patients.
METHODS
Study population
All the tissues investigated in this study were obtained 
from 213 consecutive Korean patients who underwent 
surgical resection between January 1998 and June 2008 at 
five medical centers. The GIST risk stratification was clas-
sified according to the National Institutes of Health (NIH) 
consensus classification system [7]. Retrospective in-
formation was also received concerning the patient char-
acteristics and the date of diagnosis, relapse, and death. 
Written informed consent for gene expression analyses 
was received from the patients, and the study was ap-
proved by the Institutional Review Board at Kyungpook 
National University Hospital (KNUH). 
Selection of target IGF-1/2 gene polymorphisms
Due to high number of SNPs in the human genome, the 
initial challenge was the efficient selection of the SNPs 
most likely to contribute phenotypic effects. Thus, a priori-
tizing strategy was created using public databases that 
provide diverse information on the potential phenotypic 
risks of SNPs. First candidate genes involved in IGF and 
related information were collected from web-based data-
bases that included information on the biologic pathway 
and potential biologic effects of polymorphisms. Next, 
SNPs with frequencies lower than 0.1 were excluded 
based on the allele frequencies recorded for East Asian 
populations obtained from FASTSNP (function analysis 
and selection tool for SNP). The selected SNPs were then 
scored according to certain phenotypic risks and ordered 
according to the sum of risk scores based on the algorithm 
suggested in a previous report [15]. Finally, and four IGF-1 
(＋2995C/A, ＋533C/T, IVS2-16540A/G, Ex4-177G/C) and 
one IGF-2 (IVS1＋1280A/G) gene polymorphisms were in-
cluded in the current analysis.
Genotyping of IGF-1 and IGF-2 gene polymorphisms
The genomic DNA was extracted from paraffin-em-
bedded tissue, and four IGF-1 ( ＋2995C/A,  ＋533C/T, 
IVS2-16540A/G, Ex4-177G/C) and one IGF-2 (IVS1＋
1280A/G) gene polymorphisms were determined using a 
Sequenom MassARRAY system. The genotyping was un-Ohkyoung Kwon, et al.
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SNP number Primer name Sequence
rs12579108 (+2995C/A) Foward ACGTTGGATGCAGGAGTGGATGTTCTTATG
Reverse ACGTTGGATGCCTGCCTGCAAAAATCTGAC
UEP GTGCCACCAAAATAGCTAAC
rs5742612 (+533C/T) Foward ACGTTGGATGAGATTGGAAGACAGCACTCG
Reverse ACGTTGGATGCCTCCATAGGTTCTAGGAAA
UEP AGGAAATGAGATCACACC
rs2288378 (IVS2-16540A/G) Foward ACGTTGGATGACTTTTCCAGCTCTCTCCAC
Reverse ACGTTGGATGTCCATTCTGAGCCCCAGTC
UEP TCGGGGTAGATCCTGAT
rs5742714 (Ex4-177G/C) Foward ACGTTGGATGGGCCATTCGTTACATCTGTC
Reverse ACGTTGGATGCCTCTGCCATAAGTGAATTG
UEP TGAATTGAATAATAATTTCAAATACAAT
rs3213216 (IVS1+1280A/G) Foward ACGTTGGATGTTCTGTTCCTTCCCTTCGGC
Reverse ACGTTGGATGCAGAAAGCAGGACAGGAAGC
UEP GGTGAGGGCCCAGGAAAAG
SNP, single nucleotide polymorphisms; UEP, unique-event polymorphism.
Table 1. The Sequenom MassARRAY primer sequence
dertaken using the Sequenom iPLEX platform, according 
to the manufacturer's instructions (www.sequenom.com; 
Sequenom Inc., San Diego, CA, USA). The detection of 
SNPs was carried out by analyzing the primer extension 
products generated from previously amplified genomic 
DNA using a Sequenom chip-based matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry platform. Multiplex SNP assays were de-
signed using SpectroDESIGNER ver. 2.06 (Sequenom 
Inc.). The PCR amplification took place in a 5 μL mixture 
containing 10 ng genomic DNA, 100 nM of each amplifica-
tion primer, 500 mM dNTP mix, 1.625 mM MgCl2, and 5.5 
units of HotStarTaq DNA Polymerase (Qiagen, Hilden, 
Germany). The mixture was subjected to the following 
PCR conditions: a single denaturation cycle at 95
oC for 15 
minutes, followed by 45 cycles at 94
oC for 20 seconds, 56
oC 
for 30 seconds, 72
oC for 60 seconds, and a final extension at 
72
oC for 3 minutes. Any unincorporated nucleotides in the 
PCR product were deactivated using shrimp alkaline 
phosphatase. The allele discrimination reactions were 
conducted by adding allele-specific extension primers, 
DNA polymerase, and a cocktail mixture of deoxynucleo-
tide triphosphates and di-deoxynucleotide triphosphates 
to each well. MassEXTEND clean resin (Sequenom Inc.) 
was also added to the mixture to remove any extraneous 
salts that could interfere with the MALDI-TOF analysis. 
The primer extension products were then cleaned and 
spotted onto a SpectroCHIP (Sequenom Inc.). The geno-
types were determined by spotting an aliquot of each sam-
ple onto a 384 SpectroCHIP, which was subsequently read 
using the MALDI-TOF mass spectrometer. Triplicate sam-
ples and negative controls were included to check the gen-
otyping quality. The primer sequences are summarized in 
the supplemental Table 1.
Statistical analysis
The genotypes for each SNP were analyzed as a three- 
group categorical variable (reference model) and grouped 
according to the dominant and recessive model. The sur-
vival estimates were calculated using the Kaplan-Meier 
method. The differences in overall survival (OS) or re-
lapse-free survival (RFS) according to the gene poly-
morphisms were compared using log-rank tests. For the 
multivariate analysis, Cox's proportional hazard regres-
sion model was used for the survival analyses. The analy-
ses were adjusted for age, gender, primary site of disease, 
pathology, and risk stratification. The hazard ratio and 
95% confidence interval were also estimated. A cut-off 
P-value of 0.05 was adopted for all the statistical analyses. 
All the analyses were performed using the SPSS ver. 14 
(SPSS Inc., Chicago, IL, USA). IGF-1 and IGF-2 polymorphism in GIST
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Characteristic Value
Age (yr) 62.0 (25-87)
Sex (male/female) 89/124
Primary site
Esophagus    3
Stomach 136
Small intestine  54
Colon    3
Rectum    9
Peritoneum    8
Pathology
Spindle 172
Epithelioid    5
Mixed  11
Unknown  25
Size (cm) 4.3 (1.0-20.0)
Mitoses (/50 HPFs) 4.0 (0.0-75.0)
Risk stratification (NIH consensus classification system)
Very low  14
Low  86
Intermediate  53
High  56
Unknown    4
Resection
R0 178
R1    2
R2    7
Unknown  26
Values are presented as median (range) or number.
NIH, National Institutes of Health.
Table 2. Patient characteristics (n = 213)
RESULTS
Patient characteristics and survival analysis
The patient characteristics are shown in Table 2. The me-
dian age was 62.0 years (range, 25 to 87 years), and the ratio 
of males to females was 89 to 124. The stomach was the 
most common primary site (n = 136, 63.8%). The most fre-
quently observed pathology was a spindle cell type (n = 
172, 80.8%). One hundred seventy-eight patients (83.6%) 
underwent complete resection. The median primary tu-
mor size was 4.3 cm and the median mitotic count was 4/50 
HPFs. According to the NIH consensus classification sys-
tem, the risk groups were as follows: very low (n = 14, 
6.6%), low (n = 86, 40.4%), intermediate (n = 53, 24.9%), and 
high (n = 56, 26.3%). The genotype distribution according 
to the risk and clinical outcomes are also shown in Table 3. 
With a median follow-up duration of 18.4 months, 28 re-
lapses (13.1%) were documented and 14 patients died. The 
estimated 5-year RFS and OS rates were 69.9% and 86.7%, 
respectively (Fig. 1). Plus, the survival differed according 
the NIH consensus classification system (OS, P = 0.046; 
RFS, P ＜  0.001) (Fig. 2). 
Genotype frequency effect on survival
The five IGF-1 and IGF-2 gene polymorphisms were 
successfully amplified in all cases. The frequencies of each 
genotype are shown in Table 4 and conformed to the 
Hardy-Weinberg equilibrium (P ＜ 0.05). The linkage of 
the Ex4-177G/C polymorphisms with the IVS2-16540A/G, 
＋533C/T, or ＋2995C/A was relatively strong (correlation 
coefficient, D’ = 0.88; correlation coefficient, D’ = 0.78; or 
correlation coefficient, D’ = 0.85). In the univariate and 
multivariate analyses including age, gender, primary site 
of disease, pathology, and risk stratification, none of the 
five IGF-1 and IGF-2 gene polymorphisms had a sig-
nificant effect on survival (Table 4). In a haplotype analysis 
of the 4 polymorphisms in the IGF-1 gene, none of the hap-
lotypes was found to be associated with the GIST prog-
nosis. Among the clinicopathologic variables, the risk 
stratification was a significant prognostic factor in the Cox 
model for RFS (P = 0.002). 
DISCUSSION
The prognostic impact of five SNPs of the IGF and IGF-2 
gene was investigated in patients with a surgically re-
sected GIST. However, no significant association was ob-
served between the five polymorphisms and survival in 
these patients. Given the homogenous ethnic background 
of Korean patients, any potential confounding effect due 
to ethnicity was likely to be small in the present study. 
Since IGF or its family plays a critical role in tumor-re-
lated growth and metastasis, the association of IGF gene 
polymorphisms with the risk or prognosis of several solid 
tumors, such as liver, prostate, pancreas, and breast cancer 
has already been demonstrated [12,14,16-19]. Recently, the 
current authors also reported that IGF gene poly-
morphisms are no significant association with survival in 
patients with colorectal cancer [20]. Although no data has Ohkyoung Kwon, et al.
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Reference
SNP ID
Genotype
No.
(n = 213)
Risk stratification (NIH consensus classification system)
Relapse
(n = 28)
Death
(n = 14) Very low    
 (n = 14)
Low       
(n = 86)
Intermediate 
(n = 53)
High     
(n = 56)
Unknown   
  (n = 4)
rs12579108 +2995C/A
CC
CA
AA
212
121
73
18
11
2
1
45
32
9
31
17
5
33
20
2
1
2
1
18
10
0
10
3
1
rs5742612 +533C/T
CC
CT
TT
211
20
68
123
2
2
10
9
33
43
4
14
34
3
18
35
2
1
1
1
8
19
2
1
11
rs2288378 IVS2-16540A/G
AA
AG
GG
213
9
66
138
1
5
8
5
25
56
1
20
32
2
15
39
0
1
3
2
4
22
0
2
12
rs5742714 Ex4-177G/C
GG
GC
CC
199
133
54
12
6
3
2
52
22
6
33
17
1
39
11
3
3
1
0
21
3
3
11
2
0
rs3213216 IVS1+1280A/G
AA
AG
GG
205
36
75
94
5
6
3
7
37
41
11
12
27
12
20
20
1
0
3
6
11
10
4
6
4
SNP, single nucleotide polymorphisms; NIH, National Institutes of Health.
Table 3. Genotype distribution according to the risk and clinical outcomes
Fig. 1. Survival curves for all patients.
been published on the relationship between the SNPs of 
the IGF genes and the clinical outcomes of GISTs, in-depth 
analysis of polymorphisms can provide useful in-
formation in terms of prognosis of GISTs. In fact, some 
studies on SNPs have been started to evaluate the patho-
genesis or prognosis in patients with GISTs. For example, 
Vashist et al. [21] reported that haeme oxygenase-1 promo-
tor GTn polymorphism was a potential prognostic marker. 
In the previous studies, polymorphic variants of the 
IGF-1 gene and elevated serum levels of IGF-1 protein 
have been associated with an increased risk of common 
cancers, while information on IGF-2 polymorphisms and 
their correlation with cancer risk or prognosis is scarce, 
and the results that have been published are similarly in-
consistent [17,22,23]. For example, significant associations 
between the SNPs in the  IGF-1 promoter region 
(IGF-1-2995G/A) and the risk of cancer were found in 298 
Chinese patients with colorectal cancer and 1,142 controls, 
suggesting that IGF-1 plays a role in colonic carcino-
genesis and genetically inherited variation in IGF-1 ex-
pression influences risk of colorectal cancer [13]. Tsuchiya 
et al. [19] also reported that IGF-1 (cytosine-adenine) re-
peat polymorphism in the promoter region was associated 
with prognosis in 111 prostate cancer patients with bone 
metastasis at the diagnosis. However, these poly-
morphisms were not found to have any prognostic sig-
nificance in the survival of the patients with GIST in the 
current study. There are two possible explanations for this 
result. First, the sample size of 213 patients was relatively 
small to draw a statistically significant power in the poly-IGF-1 and IGF-2 polymorphism in GIST
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Fig. 2. Survival curves of overall survival (A) and relapse-free survival (B) according to National Institutes of Health consensus classification
system.
Reference  
SNP ID
Genotype No. MAF
Relapse-free survival Overall survival
 Univariate     Multivariate
P-value
Univariate      Multivariate
P-value
P-value Hazard ratio (CI) Log-rank Hazard ratio (CI)
rs12579108 +2995C/A
CC
CA
AA
212
121
  73
  18
0.257 0.375
1
0.298 (0.002-5.114)
0.119 (0.000-4.010)
0.733
0.645
0.473
0.806
1
   0.003 (0.000-3.289)
＜0.001 (0.000-4.569)
0.558
0.964
0.952
rs5742612 +533C/T
CC
CT
TT
211
  20
  68
123
0.256 0.548
1
0.526 (0.053-5.256)
0.391 (0.002-9.699)
0.850
0.585
0.739
0.240
1
    0.088 (0.004-1.778)
＜0.001 (0.000-1.218)
0.284
0.113
0.958
rs2288378 IVS2 -16540A/G
AA
AG
GG
213
    9
  66
138
0.197 0.121
1
0.146 (0.018-1.210)
0.294 (0.015-5.746)
0.186
0.075
0.420
0.256
1
      0.025 (0.000-23.922)
    0.273 (0.034-9.416)
0.574
0.292
0.995
rs5742714 Ex4 -177G/C
GG
GC
CC
199
133
  54
  12
0.196 0.280
1
1.752 (0.156-1.967)
6.215 (0.533-7.249)
0.343
0.650
0.145
0.490
1
    12.457 (0.015-10.113)
＜0.001 (0.000-1.640)
0.760
0.461
0.963
rs3213216 IVS1 +1280A/G
AA
AG
GG
205
  36
  75
  94
0.359 0.162
1
2.059 (0.787-5.385)
2.313 (0.724-7.391)
0.250
0.141
0.157
0.228
1
      2.110 (0.401-11.093)
      3.516 (0.539-22.920)
0.406
0.378
0.189
P-values correspond to univariate using log-lank test and multivariate Cox model adjusted for age, gender, primary site of disease, 
pathology, and risk stratification.
IGF, insulin-like growth factors; SNP, single nucleotide polymorphisms; MAF, minor allele frequency; CI, confidence interval.
Table 4. Univariate and multivariate survival analysis according to five IGF-1 and IGF-2 gene polymorphisms
morphism study. Second, somatic alteration in the process 
of tumorigenesis may have developed, as the DNA was 
extracted from paraffin-embedded tumor tissue, although 
no data has been reported on differences between germ-
line and somatic SNPs of the IGF gene. Interestingly, some 
investigators have reported that IGF-1 receptor was 
strongly expressed in pediatric or wild type GIST by SNP 
analysis [24,25]. These studies implicate IGF-1 receptor as 
a potential therapeutic target in these patients with GIST. 
The present study also evaluated a SNP of IGF-2 gene, Ohkyoung Kwon, et al.
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yet it was not found to have a significant influence on the 
prognosis of GIST. In a previous study by Suzuki et al. [14] 
that compared the frequency of 6 SNPs of IGF-1 and IGF-2 
in a large-scale case control study to determine whether 
genetic variations of IGF modify pancreatic cancer risk, 
the IGF-2 3’-UTR Ex4 -233T/T genotype was significantly 
associated with a reduced risk of pancreatic cancer. In con-
trast, Lai et al. [22] reported that polymorphism of IGF-2 
gene is not likely to contribute to the pathogenesis of pros-
tate cancer or be involved in tumor progression, although 
the expression of IGF-2 and androgen receptors in pros-
tate suggested that IGF-2 plays a role in regulating an-
drogen receptor expression in prostate cancer cells. Thus, 
given these results, a better understanding of the distinct 
polymorphisms in IGF genes and protein expression regu-
lation in different cancers will be a critical step toward the 
clinical utilization of this new subclass of genetic varia-
tions in management of GIST.
In conclusion, none of the five IGF-1 and IGF-2 gene 
polymorphisms investigated in this study was found to be 
an independent prognostic marker for Korean patients 
with surgically resected GISTs. However, further studies 
on a larger scale are warranted to clarify the role of IGF and 
its family gene polymorphisms as a prognostic biomarker 
for GIST patients.
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